307 related articles for article (PubMed ID: 6937239)
21. Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate.
Liliemark JO; Plunkett W
Cancer Res; 1986 Mar; 46(3):1079-83. PubMed ID: 3484676
[TBL] [Abstract][Full Text] [Related]
22. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Gandhi V; Plunkett W
Cancer Res; 1988 Jan; 48(2):329-34. PubMed ID: 3335008
[TBL] [Abstract][Full Text] [Related]
23. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
Roberts D; Peck C; Hilliard S; Wingo W
Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642
[TBL] [Abstract][Full Text] [Related]
24. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
[TBL] [Abstract][Full Text] [Related]
25. Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes.
Koehl U; Hollatz G; Rohrbach E; Visschedyk K; Cinatl J; Kornhuber B; Kreuter J; Mutschler E; Schwabe D
Cancer Chemother Pharmacol; 2007 Sep; 60(4):467-77. PubMed ID: 17171362
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Paul CY; Gahrton CG; Peterson CO
Cancer Res; 1985 May; 45(5):2373-5. PubMed ID: 3986778
[TBL] [Abstract][Full Text] [Related]
27. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
28. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.
Jamieson GP; Finch LR; Snook M; Wiley JS
Cancer Res; 1987 Jun; 47(12):3130-5. PubMed ID: 3472653
[TBL] [Abstract][Full Text] [Related]
29. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
Grant S; Bhalla K; Rauscher F; Cadman E
Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
Yamauchi T; Kawai Y; Kishi S; Goto N; Urasaki Y; Imamura S; Fukushima T; Yoshida A; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 May; 92(5):546-53. PubMed ID: 11376564
[TBL] [Abstract][Full Text] [Related]
32. ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.
Liliemark JO; Gahrton G; Paul CY; Peterson CO
Semin Oncol; 1987 Jun; 14(2 Suppl 1):167-71. PubMed ID: 3589691
[TBL] [Abstract][Full Text] [Related]
33. Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo.
Spriggs D; Robbins G; Ohno Y; Kufe D
Cancer Res; 1987 Dec; 47(24 Pt 1):6532-6. PubMed ID: 3479246
[TBL] [Abstract][Full Text] [Related]
34. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
Plunkett W; Iacoboni S; Keating MJ
Scand J Haematol Suppl; 1986; 44():51-9. PubMed ID: 3457439
[No Abstract] [Full Text] [Related]
35. Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells.
Bhalla K; Birkhofer M; Arlin Z; Grant S; Lutzky J; Safah H; Graham G
Exp Hematol; 1991 Aug; 19(7):669-73. PubMed ID: 1893953
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
Riva CM; Rustum YM; Preisler HD
Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925
[No Abstract] [Full Text] [Related]
37. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow.
Tanaka M
Leuk Res; 1993 Jul; 17(7):585-92. PubMed ID: 8326741
[TBL] [Abstract][Full Text] [Related]
38. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
39. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
Danhauser LL; Rustum YM
Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
[TBL] [Abstract][Full Text] [Related]
40. Prediction of sensitivity to 1-beta-D-arabinofuranosylcytosine by the plateau level of its 5'-triphosphate in human lymphoblastic cell lines in vitro.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Eur J Cancer Clin Oncol; 1983 Jul; 19(7):941-4. PubMed ID: 6576907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
